BackBioNTech SE Overview
BioNTech SE - ADR

BioNTech SE Target Price

Where could BNTX trade next? Consensus target price: $130.

Get informed when a big investor buys or sells

+ Follow

Share Price

$92.74

Average Target Price

$130.0040.2% upside

5 analysts in the last 4 months

High: $158 | Low: $96

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-05Canaccord Genuity$14253.1% upsideOpen
2026-07-08Morgan Stanley$11928.3% upsideOpen
2026-05-27UBS$13545.6% upsideOpen
2026-05-21Bernstein$963.5% upsideOpen
2026-05-06Canaccord Genuity$15870.4% upsideOpen
2026-04-10Morgan StanleyTerence Flynn$12635.9% upsideOpen
2026-03-11BMO CapitalEvan David Seigerman$12838% upsideOpen
2026-03-10JefferiesAkash Tewari$13848.8% upsideOpen
2026-03-10Truist FinancialAsthika Goonewardene$15567.1% upsideOpen
2026-03-10Morgan Stanley$12838% upsideOpen
2026-02-02Leerink Partners$11321.8% upsideOpen
2026-01-16Goldman Sachs$14253.1% upsideOpen
2025-12-11Berenberg BankHarry Gillis$15567.1% upsideOpen
2025-12-11H.C. WainwrightRaghuram Selvaraju$14051% upsideOpen
2025-11-03Morgan Stanley$13444.5% upsideOpen
2025-10-10Morgan StanleyTerence Flynn$13141.3% upsideOpen
2025-08-05Wells FargoMohit Bansal$15061.7% upsideOpen
2025-07-10Morgan StanleyTerence Flynn$13343.4% upsideOpen
2025-06-02Leerink PartnersDaina Graybosch$11220.8% upsideOpen
2025-05-29Goldman SachsAsad Haider$11018.6% upsideOpen
2025-05-14H.C. WainwrightRobert Burns$13444.5% upsideOpen
2025-04-01H.C. Wainwright$14556.4% upsideOpen
2024-11-19Evercore ISICory Kasimov$12534.8% upsideOpen
2024-11-13Leerink PartnersDaina Graybosch$12130.5% upsideOpen
2024-11-08Goldman SachsChris Shibutani$13747.7% upsideOpen
2024-11-04BMO CapitalEtzer Darout$12635.9% upsideOpen
2024-09-23Morgan StanleyTerence Flynn$14556.4% upsideOpen
2024-09-17JefferiesAkash Tewari$15061.7% upsideOpen
2024-09-16Bank of America SecuritiesTazeen Ahmad$15061.7% upsideOpen
2024-09-13JefferiesAkash Tewari$963.5% upsideOpen
2024-08-06Deutsche BankEmmanuel Papadakis$952.4% upsideOpen
2024-08-05Morgan StanleyTerence Flynn$930.3% upsideOpen
2024-08-02HSBCYifeng Liu$1018.9% upsideOpen
2024-06-26H.C. WainwrightRaghuram Selvaraju$11321.8% upsideOpen
2024-05-13Evercore ISICory Kasimov$1007.8% upsideOpen
2024-05-07BMO CapitalEtzer Darout$12231.6% upsideOpen
2024-03-22HSBCYifeng Liu$903% downsideOpen
2024-03-21Canaccord GenuityWilliam Maughan$17184.4% upsideOpen
2024-03-21BMO CapitalEtzer Darout$12332.6% upsideOpen
2024-03-21Goldman SachsChris Shibutani$911.9% downsideOpen
2023-01-31Goldman Sachs$15668.2% upsideOpen
2022-12-02Leerink PartnersMani Foroohar$8112.7% downsideOpen
2022-05-17UBSAndrew Ang$16881.2% upsideOpen
2022-05-10Morgan StanleyMatthew Harrison$195110.3% upsideOpen
2022-04-16H.C. WainwrightRobert Burns$298221.3% upsideOpen
2022-04-10Canaccord GenuityArlinda Lee$300223.5% upsideOpen
2022-01-21UBSEliana Merle$17083.3% upsideOpen
2021-12-22Kempen & CoSuzanne van Voorthuizen$350277.4% upsideOpen
2021-12-09Leerink PartnersDaina Graybosch$253172.8% upsideOpen
2021-10-04Bryan Garnier & Co LtdOlga Smolentseva$359287.1% upsideOpen

BioNTech SE (BNTX) FAQ

BioNTech SE (BNTX) currently reports a target price of $130. Use the charts on this page to explore BioNTech SE's target price history and peer comparisons.

Analysts' average 12-month price target for BioNTech SE is $130, about 40.2% upside from the current share price of $92.74. That spread summarizes where covering analysts expect the stock could trade over the next year, not a guarantee. Review the individual firm targets on this page — a wide high-to-low range often means opinion is split.

Start with the current target price of $130, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for BioNTech SE, and consider following BNTX for alerts when major investors trade the stock.

BioNTech SE is classified in the Healthcare sector. On target price, it currently shows $130. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BNTX with unrelated industries.